1. Home
  2. TJX vs NVO Comparison

TJX vs NVO Comparison

Compare TJX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TJX Companies Inc. (The)

TJX

TJX Companies Inc. (The)

HOLD

Current Price

$167.90

Market Cap

173.6B

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$44.04

Market Cap

197.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TJX
NVO
Founded
1962
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
173.6B
197.4B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
TJX
NVO
Price
$167.90
$44.04
Analyst Decision
Strong Buy
Hold
Analyst Count
16
11
Target Price
$169.00
$51.00
AVG Volume (30 Days)
5.5M
11.2M
Earning Date
05-20-2026
05-06-2026
Dividend Yield
1.23%
3.19%
EPS Growth
14.32
N/A
EPS
1.19
N/A
Revenue
$29,078,407,000.00
N/A
Revenue This Year
$6.75
N/A
Revenue Next Year
$5.81
$3.70
P/E Ratio
$140.92
$13.60
Revenue Growth
6.04
N/A
52 Week Low
$119.84
$35.12
52 Week High
$167.92
$81.44

Technical Indicators

Market Signals
Indicator
TJX
NVO
Relative Strength Index (RSI) 69.60 52.84
Support Level $152.63 $43.35
Resistance Level N/A $46.05
Average True Range (ATR) 3.18 1.36
MACD 1.52 -0.28
Stochastic Oscillator 88.14 61.14

Price Performance

Historical Comparison
TJX
NVO

About TJX TJX Companies Inc. (The)

Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: